These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25381974)

  • 21. Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies.
    Barbosa MD; Gokemeijer J; Martin AD; Bush A
    Anal Biochem; 2013 Oct; 441(2):174-9. PubMed ID: 23886888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
    Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
    J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of biologic therapies: causes and consequences.
    Boehncke WH; Brembilla NC
    Expert Rev Clin Immunol; 2018 Jun; 14(6):513-523. PubMed ID: 29683362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
    Steenholdt C; Ainsworth MA; Tovey M; Klausen TW; Thomsen OO; Brynskov J; Bendtzen K
    Ther Drug Monit; 2013 Aug; 35(4):530-8. PubMed ID: 23765033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity assessment in non-clinical studies.
    Swanson SJ; Bussiere J
    Curr Opin Microbiol; 2012 Jun; 15(3):337-47. PubMed ID: 22770538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.
    Marinari B; Botti E; Bavetta M; Spallone G; Zangrilli A; Talamonti M; Richetta A; Chimenti S; Costanzo A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S11-4. PubMed ID: 25381966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection.
    Bendtzen K
    Front Immunol; 2015; 6():109. PubMed ID: 25904911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories.
    Bader LI; Solberg SM; Kaada SH; Bolstad N; Warren DJ; Gavasso S; Gjesdal CG; Vedeler CA
    Scand J Immunol; 2017 Sep; 86(3):165-170. PubMed ID: 28561325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.
    Keiserman M; Codreanu C; Handa R; Xibillé-Friedmann D; Mysler E; Briceño F; Akar S
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1049-57. PubMed ID: 24961616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development.
    Jiang H; Xu W; Titsch CA; Furlong MT; Dodge R; Voronin K; Allentoff A; Zeng J; Aubry AF; DeSilva BS; Arnold ME
    Anal Chem; 2014 Mar; 86(5):2673-80. PubMed ID: 24506335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
    Ben-Horin S; Waterman M; Kopylov U; Yavzori M; Picard O; Fudim E; Awadie H; Weiss B; Chowers Y
    Clin Gastroenterol Hepatol; 2013 Apr; 11(4):444-7. PubMed ID: 23103905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I.
    Wessels U; Poehler A; Moheysen-Zadeh M; Zadak M; Staack RF; Umana P; Heinrich J; Stubenrauch K
    Bioanalysis; 2016 Oct; 8(20):2135-45. PubMed ID: 27582032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
    Svenson M; Geborek P; Saxne T; Bendtzen K
    Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing specificity for immunogenicity assays.
    Swanson SJ; Chirmule N
    Bioanalysis; 2009 Jun; 1(3):611-7. PubMed ID: 21083156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of therapeutic monoclonal antibodies.
    Pendley C; Schantz A; Wagner C
    Curr Opin Mol Ther; 2003 Apr; 5(2):172-9. PubMed ID: 12772508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
    Smith HW; Butterfield A; Sun D
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The enzyme-linked immunosorbent assay (ELISA) (theory, technique and applications).
    Voller A
    Ric Clin Lab; 1978; 8(4):289-98. PubMed ID: 366726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies.
    Beeg M; Nobili A; Orsini B; Rogai F; Gilardi D; Fiorino G; Danese S; Salmona M; Garattini S; Gobbi M
    Sci Rep; 2019 Feb; 9(1):2064. PubMed ID: 30765716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calibration-free concentration analysis for quantification of anti-drug specific antibodies in polyclonal positive control antibodies and in clinical samples.
    Aniol-Nielsen C; Toft-Hansen H; Dahlbäck M; Nielsen CH; Solberg H
    J Immunol Methods; 2021 Oct; 497():113002. PubMed ID: 33640327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.